Mineralys’ MLS-101 is being analysed in a Phase II Target-HTN trial in patients with uncontrolled hypertension. Credit: John Campbell / Flickr (Creative Commons).

Mineralys Therapeutics has raised $118m in a Series B funding round to advance the development of MLS-101, a new targeted treatment for hypertension.

RA Capital Management and Andera Partners led the financing round with participation from new investors RTW Investments, Rock Springs Capital, SR One Capital Management and Sectoral Asset Management among others.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Current investors, including Catalys Pacific, HBM Healthcare Investments, Samsara BioCapital and Adams Street Partners also took part in the financing. 

Andera partner Olivier Litzka and RA Capital Management partner Derek DiRocco will join the board of directors of Mineralys as part of the financing.

An inhibitor of aldosterone synthase, MLS-101 is presently being analysed in a Phase II Target-HTN clinical trial in patients with uncontrolled hypertension. 

The company expects to report top-line data from this trial later this year.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Licenced from Mitsubishi Tanabe Pharma, MLS-101 is claimed to lower plasma aldosterone levels by hindering the CYP11B2 pathway linked to aldosterone synthesis, without the unexpected effects of inhibiting the mineralocorticoid receptor.

Abnormally raised aldosterone is an underlying cause of hypertension rampant in a substantial portion of patients.

The therapy was analysed in a Phase I programme in healthy subjects that established the aldosterone lowering effects of MLS-101 and showed a safe and tolerable clinical profile. 

In addition to hypertension, MLS-101 may be beneficial for end-stage renal disease, cardiac heart failure and cardiac mortality.

Mineralys Therapeutics CEO Jon Congleton said: “MLS-101 has the potential to be a paradigm-shifting treatment by normalizing plasma aldosterone levels, selectively, without the untoward effects of blocking the mineralocorticoid receptor. 

“This financing will allow us to further our clinical programme to unlock the value of MLS-101.”

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact